PL2602258T3 - Jednowodna sól metanosulfonianowa N-[5-(aminosulfonylo)-4-metylo-1,3- tiazol-2-ilo]-N-metylo-2-[4-(2-pirydynylo)fenylo]acetamidu - Google Patents

Jednowodna sól metanosulfonianowa N-[5-(aminosulfonylo)-4-metylo-1,3- tiazol-2-ilo]-N-metylo-2-[4-(2-pirydynylo)fenylo]acetamidu

Info

Publication number
PL2602258T3
PL2602258T3 PL13157396T PL13157396T PL2602258T3 PL 2602258 T3 PL2602258 T3 PL 2602258T3 PL 13157396 T PL13157396 T PL 13157396T PL 13157396 T PL13157396 T PL 13157396T PL 2602258 T3 PL2602258 T3 PL 2602258T3
Authority
PL
Poland
Prior art keywords
methyl
aminosulfonyl
thiazol
pyridinyl
phenyl
Prior art date
Application number
PL13157396T
Other languages
English (en)
Inventor
Schwab Wilfried Dr
Alexander Birkmann
Kurt Vögtli
Dieter Haag
Andreas Lender
Alfons Grunenberg
Birgit Keil
Joachim Rehse
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of PL2602258T3 publication Critical patent/PL2602258T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/46Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
PL13157396T 2011-09-26 2012-09-26 Jednowodna sól metanosulfonianowa N-[5-(aminosulfonylo)-4-metylo-1,3- tiazol-2-ilo]-N-metylo-2-[4-(2-pirydynylo)fenylo]acetamidu PL2602258T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11007823A EP2573086A1 (en) 2011-09-26 2011-09-26 N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP2011007823 2011-09-26
EP12762300.7A EP2598501B1 (en) 2011-09-26 2012-09-26 N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP13157396.6A EP2602258B8 (en) 2011-09-26 2012-09-26 N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate

Publications (1)

Publication Number Publication Date
PL2602258T3 true PL2602258T3 (pl) 2014-08-29

Family

ID=46889067

Family Applications (2)

Application Number Title Priority Date Filing Date
PL12762300T PL2598501T3 (pl) 2011-09-26 2012-09-26 Jednowodna sól metanosulfonianowa N-[5-(aminosulfonylo)-4-metylo-1,3-tiazol-2-ilo]-N-metylo-2-[4-(2-pirydynylo)fenylo]acetamidu
PL13157396T PL2602258T3 (pl) 2011-09-26 2012-09-26 Jednowodna sól metanosulfonianowa N-[5-(aminosulfonylo)-4-metylo-1,3- tiazol-2-ilo]-N-metylo-2-[4-(2-pirydynylo)fenylo]acetamidu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL12762300T PL2598501T3 (pl) 2011-09-26 2012-09-26 Jednowodna sól metanosulfonianowa N-[5-(aminosulfonylo)-4-metylo-1,3-tiazol-2-ilo]-N-metylo-2-[4-(2-pirydynylo)fenylo]acetamidu

Country Status (29)

Country Link
US (1) US9340535B2 (pl)
EP (3) EP2573086A1 (pl)
JP (2) JP6161614B2 (pl)
KR (4) KR20190104249A (pl)
CN (2) CN105541829A (pl)
AR (3) AR088043A1 (pl)
AU (2) AU2012314536B2 (pl)
BR (1) BR112014003245B1 (pl)
CA (1) CA2791142C (pl)
CL (1) CL2014000149A1 (pl)
DK (2) DK2602258T3 (pl)
ES (2) ES2466221T3 (pl)
HK (1) HK1220978A1 (pl)
HR (1) HRP20140351T1 (pl)
IL (2) IL230152A (pl)
IN (1) IN2014DN01993A (pl)
JO (2) JO3037B1 (pl)
MX (2) MX371088B (pl)
MY (2) MY190878A (pl)
PE (1) PE20141148A1 (pl)
PH (1) PH12015502801B1 (pl)
PL (2) PL2598501T3 (pl)
PT (1) PT2598501E (pl)
RU (2) RU2669388C1 (pl)
SG (1) SG10201407430TA (pl)
TW (2) TWI567070B (pl)
UA (2) UA119574C2 (pl)
WO (1) WO2013045479A1 (pl)
ZA (2) ZA201401773B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2573085A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
CA3018026A1 (en) * 2016-04-06 2017-10-12 Innovative Molecules Gmbh Aminothiazole derivatives useful as antiviral agents
PT3544976T (pt) * 2016-11-28 2021-05-18 Aicuris Anti Infective Cures Gmbh Hemi-hidrato da base livre de n-[5-(aminossulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricação e suas utilizações
WO2018095576A1 (en) * 2016-11-28 2018-05-31 Aicuris Anti-Infective Cures Gmbh Topical pharmaceutical formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide
TWI808591B (zh) * 2016-11-28 2023-07-11 德商艾庫瑞斯公司 N-[5-(胺基磺醯基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)-苯基]-乙醯胺之游離鹼之硫酸鹽、其醫藥調配物及其用途
KR102335327B1 (ko) 2017-04-28 2021-12-03 현대자동차 주식회사 수냉식 이지알 쿨러
UA126076C2 (uk) 2017-06-28 2022-08-10 Айкуріс Ґмбг Унд Ко. Кґ Пристрій для інтравагінального введення прителівіру
MA50609B1 (fr) 2017-10-05 2023-03-31 Innovative Molecules Gmbh Énantiomères de thiazoles substitués utilisés comme composés antiviraux
JP7150368B2 (ja) * 2018-07-06 2022-10-11 フェーノ・セラピューティクス・カンパニー・リミテッド チアゾール系化合物の結晶形およびその応用
WO2020061295A1 (en) * 2018-09-19 2020-03-26 Modernatx, Inc. High-purity peg lipids and uses thereof
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
WO2024047508A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. Pharmaceutical compositions for herpes virus
WO2024047507A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. A novel crystalline form of pritelivir
WO2024047506A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. A novel crystalline form of pritelivir

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2000000109A (es) 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
DE10129716A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10129717A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10129714A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
DE10131128A1 (de) * 2001-06-28 2003-01-16 Bayer Ag Sekundäre Sulfonamide
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
DE102005014248A1 (de) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
JP2007314516A (ja) * 2006-04-25 2007-12-06 Daiichi Sankyo Co Ltd 2以上の置換基を有するベンゼン化合物を含有する医薬
CN101490001A (zh) * 2006-06-09 2009-07-22 Icos股份有限公司 用作dp-2拮抗剂的取代的苯乙酸
AR070127A1 (es) * 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP2573085A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range

Also Published As

Publication number Publication date
NZ621615A (en) 2016-04-29
JO3037B1 (ar) 2016-09-05
AU2012314536B2 (en) 2016-01-14
TWI532739B (zh) 2016-05-11
ES2462492T3 (es) 2014-05-23
IL234405A (en) 2015-04-30
ZA201401773B (en) 2015-12-23
MY190878A (en) 2022-05-13
TW201625603A (zh) 2016-07-16
CN103842359A (zh) 2014-06-04
EP2602258A1 (en) 2013-06-12
MY185063A (en) 2021-04-30
KR20170055565A (ko) 2017-05-19
WO2013045479A1 (en) 2013-04-04
KR20190104249A (ko) 2019-09-06
BR112014003245B1 (pt) 2021-11-09
RU2669388C1 (ru) 2018-10-11
MX338736B (es) 2016-04-29
KR20140066704A (ko) 2014-06-02
UA119574C2 (uk) 2019-07-10
AR116394A2 (es) 2021-05-05
RU2014107430A (ru) 2015-11-10
JO3734B1 (ar) 2021-01-31
CA2791142A1 (en) 2013-03-26
PH12015502801A1 (en) 2016-10-03
RU2620604C2 (ru) 2017-05-29
IL230152A (en) 2015-04-30
KR20180088530A (ko) 2018-08-03
UA115317C2 (uk) 2017-10-25
TWI567070B (zh) 2017-01-21
BR112014003245A2 (pt) 2017-03-01
EP2573086A1 (en) 2013-03-27
AR088043A1 (es) 2014-05-07
PL2598501T3 (pl) 2014-08-29
CN103842359B (zh) 2016-05-25
MX371088B (es) 2020-01-16
SG10201407430TA (en) 2014-12-30
MX2014003389A (es) 2014-07-09
US20140221433A1 (en) 2014-08-07
EP2602258B1 (en) 2014-03-19
EP2602258B8 (en) 2016-09-28
AR120291A2 (es) 2022-02-09
AU2012314536A1 (en) 2014-02-06
CA2791142C (en) 2017-08-01
US9340535B2 (en) 2016-05-17
JP2014528948A (ja) 2014-10-30
EP2598501B1 (en) 2014-03-12
PE20141148A1 (es) 2014-09-15
ES2466221T8 (es) 2016-09-13
PT2598501E (pt) 2014-06-25
AU2015260762B2 (en) 2016-06-09
ES2466221T3 (es) 2014-06-09
JP2017114859A (ja) 2017-06-29
DK2602258T3 (da) 2014-04-22
DK2598501T3 (da) 2014-04-22
IN2014DN01993A (pl) 2015-05-15
CL2014000149A1 (es) 2014-09-05
NZ718867A (en) 2016-05-27
AU2015260762A1 (en) 2016-02-04
TW201317234A (zh) 2013-05-01
CN105541829A (zh) 2016-05-04
EP2598501A1 (en) 2013-06-05
JP6353022B2 (ja) 2018-07-04
PH12015502801B1 (en) 2016-10-03
HRP20140351T1 (hr) 2014-07-04
JP6161614B2 (ja) 2017-07-12
HK1220978A1 (zh) 2017-05-19
ZA201408734B (en) 2016-08-31
KR101768295B1 (ko) 2017-08-14

Similar Documents

Publication Publication Date Title
ZA201408734B (en) N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
ZA201401774B (en) N-[5-(aminosulfonyl)-4-methly-1,3-thiazol-2-yl]-n-methly-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations
IL242279A0 (en) Compounds of 3-chloro-3]-n-(pyrimidine-2-ylamino)phenyl]substituted propanamide and their salts
HK1111888A1 (en) Pharmaceutical preparation of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2- yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide n-[5-()-4--13--2-]-n--2-[4-(2-)]
IL259824B (en) History of 2-[3-(azolyl)phenyl]-3,1-thiazole-5-carboxylic acid for use as drugs
HK1217487A1 (zh) 用於治療成癮的作為乙醛脫氫酶- 抑制劑的 -氧基- -二氫-吡啶- -基 -芐基 -苯甲酰胺衍生物
PT3848369T (pt) Hemi-hidrato da base livre de n-[5-(aminossulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricação e suas utilizações
NO2020032I1 (no) Avatrombopag and pharmaceutically acceptable salts thereof, particularly avatrombopag maleate (1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl) thiazol-2-yl] carbamoyl} pyridin-2-yl) piperidine-4-carboxylic acid maleic acid salt
IL267557B (en) Process for the preparation of 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl[ethoxy]phenyl]methyl]-2,4-thiazolidinedione and their salts
IL243913A0 (en) 2-[5-[n-(4-fluorophenyl)carbamoyl]pyrimidine-2-ylsulfonylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid
PT2602258E (pt) Monohidrato de mesilato de n-[5-aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida
BR112014003246A2 (pt) ácido n-[5-(aminossulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]acetamida monometanossulfônico monohidratado cristalino e composição farmacêutica contendo partículas do mesmo